NCT00681044 - HD Melphalan and SCT in Patients With IGDD or LCDD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL

filgrastim

16 mcg/kg daily beginning 3 days prior to SCC through day before final SCC

DRUG

melphalan

70-100 mg/m2/day will be administered intravenously on Days -3 and -2

PROCEDURE

Stem Cell Infusion

infusion of previously collected stem cells on Day 0

Trial Locations (1)

Boston University Cancer Research Center, Boston